Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Go back to Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments| (NASDAQ: NTLA) | Delayed: 12.68 -0.08 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.76 | 52 Week High | $30.40 | |||
| Open | $12.91 | 52 Week Low | $11.86 | |||
| Day High | $12.92 | P/E | N/A | |||
| Day Low | $12.40 | EPS | $0.00 | |||
| Volume | 3,002,223 | |||||
| Regeneron (NASDAQ: REGN) | Delayed: 843.47 -8.56 (1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $852.03 | 52 Week High | $592.36 | |||
| Open | $858.18 | 52 Week Low | $325.35 | |||
| Day High | $859.34 | P/E | 221.38 | |||
| Day Low | $837.63 | EPS | $3.81 | |||
| Volume | 496,184 | |||||
